Karyopharm Therapeutics (KPTI) Reports Q4 Loss of $0.81/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Jefferies Remains Sidelined on Karyopharm Therapeutics (KPTI) Following 4Q - PT to $10
March 15, 2016 8:39 AM EDTJefferies reiterated a Hold rating on Karyopharm Therapeutics (NASDAQ: KPTI), and cut the price target to $10.00 (from $14.00), following the company's 4Q earnings report. Total operating expenses for 4Q were $29.3M consisting of $24.1M of R&D vs. a $24.5M estimate and... More
